Agenda

April 5-6 | New York City

Available DatesRegister

Friday April 05, 2024

  • 8:00 AM – 8:05 AM

    Welcome

    • Co-Chair
      • John LeonardMD
  • 8:05 AM – 8:20 AM

    Session 1: Debate-Chemotherapy Based Approaches Are Best for Initial Therapy for Mantle Cell lymphoma

    • Speaker
      • Peter MartinMD
  • 8:20 AM – 8:35 AM

    Session 1: Debate-Novel, “Non-Chemotherapy” Approaches Are Best for Initial Therapy for Mantle Cell Lymphoma

    • Speaker
      • Jia RuanMD, PhD
  • 8:35 AM – 8:45 AM

    Session 1: PANEL DISCUSSION

    • Moderator
      • John LeonardMD
    • Panelist
      • Jia RuanMD, PhD
      • Peter MartinMD
  • 8:45 AM – 9:00 AM

    Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive CAR-T Cell Therapy?

    • Speaker
      • Samuel YamshonMD
  • 9:00 AM – 9:15 AM

    Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive Novel Agents?

    • Speaker
      • Barbara ProMD
  • 9:15 AM – 9:25 AM

    Session 2: PANEL DISCUSSION

    • Moderator
      • John LeonardMD
    • Panelist
      • Barbara ProMD
      • Samuel YamshonMD
  • 9:25 AM – 9:55 AM

    Session 3: Reevaluating Frontline Therapy and Beyond for Hodgkin Lymphoma: Strategies for Optimal Clinical Decision-Making and Targeted Therapy across Patient Groups

    • Speaker
      • Andrew EvensDO, MBA, MSc
  • 9:55 AM – 10:05 AM

    Session 3: Post Session Survey and Q&A

    • Moderator
      • John LeonardMD
    • Panelist
      • Andrew EvensDO, MBA, MSc
  • 10:05 AM – 10:15 AM

    Exhibit Hall Break

  • 10:15 AM – 11:15 AM

    Non-CME Innovation Theater (Sponsored by Lilly USA, LLC)

  • 11:15 AM – 11:45 AM

    Session 4: Targeted Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    • Speaker
      • John AllanMD
  • 11:45 AM – 11:55 AM

    Session 4: Post Session Survey and Q&A

    • Moderator
      • John LeonardMD
    • Panelist
      • John AllanMD
  • 11:55 AM – 12:25 PM

    Session 5: Evaluating Targeted Therapeutic Options in Relapsed/Refractory Follicular Lymphoma

    • Speaker
      • John LeonardMD
  • 12:25 PM – 12:35 PM

    Session 5: Post Session Survey and Q&A

  • 12:35 PM – 12:45 PM

    Exhibit Hall Break

  • 12:45 PM – 1:45 PM

    Non-CME Innovation Theater (Sponsored by AbbVie Medical Affairs)

  • 1:45 PM – 2:00 PM

    Session 6: Debate- CAR-T Cells Should Be Rarely Used in Relapsed Follicular Lymphoma

    • Speaker
      • Peter MartinMD
  • 2:00 PM – 2:15 PM

    Session 6: Debate- CAR-T Cells Should Be More Often Used in Relapsed Follicular Lymphoma

    • Speaker
      • Caron JacobsonMD, MMSc
  • 2:15 PM – 2:25 PM

    Session 6: PANEL DISCUSSION

    • Moderator
      • John LeonardMD
    • Panelist
      • Caron JacobsonMD, MMSc
      • Peter MartinMD
  • 2:25 PM – 2:55 PM

    Session 7: Case Discussions in Leukemia

    • Moderator
      • Jessica AltmanMD
    • Panelist
      • Amer ZeidanMBBS, MHS
      • Elias JabbourMD
  • 2:55 PM – 3:05 PM

    Session 7: Post Session Survey and Q&A

    • Moderator
      • Jessica AltmanMD
    • Panelist
      • Elias JabbourMD
  • 3:05 PM – 3:15 PM

    Exhibit Hall Break

  • 3:15 PM – 4:15 PM

    Non-CME Innovation Theater (Sponsored by Bristol Myers Squibb)

  • 4:15 PM – 4:30 PM

    Session 8: Debate- The Right Treatment for R/R ALL Is –Monoclonal Antibody

    • Speaker
      • Elias JabbourMD
  • 4:30 PM – 4:45 PM

    Session 8: Debate- The Right Treatment for R/R ALL Is – CAR-T

    • Speaker
      • Jae ParkMD
  • 4:45 PM – 4:55 PM

    Session 8: PANEL DISCUSSION

    • Moderator
      • Jessica AltmanMD
    • Panelist
      • Elias JabbourMD
      • Jae ParkMD
  • 4:55 PM – 5:10 PM

    Session 9: Transplant considerations for MDS patients undergoing AlloHSCT

    • Speaker
      • Aditi ShastriMD
  • 5:10 PM – 5:25 PM

    Session 9: Therapeutic Updates for higher risk MDS

    • Speaker
      • Amer ZeidanMBBS, MHS
  • 5:25 PM – 5:35 PM

    Session 9: PANEL DISCUSSION

    • Moderator
      • Jessica AltmanMD
    • Panelist
      • Aditi ShastriMD
      • Amer ZeidanMBBS, MHS

Saturday April 06, 2024

  • 8:40 AM – 8:45 AM

    Welcome

    • Co-Chair
      • Jessica AltmanMD
  • 8:45 AM – 9:00 AM

    Session 10: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for IC - YES

    • Speaker
      • Kristen O'DwyerMD
  • 9:00 AM – 9:15 AM

    Session 10: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for IC - NO

    • Presenter
      • Jessica AltmanMD
  • 9:15 AM – 9:25 AM

    Session 10: PANEL DISCUSSION

    • Moderator
      • Jessica AltmanMD
    • Panelist
      • Kristen O'DwyerMD
  • 9:25 AM – 9:55 AM

    Session 11: Advancing Risk Stratification and Symptom Management in Patients with Low- and Intermediate-Risk Myelodysplastic Syndromes

    • Speaker
      • Aditi ShastriMD
  • 9:55 AM – 10:05 AM

    Session 11- Post Session Survey and Q&A

    • Moderator
      • Jessica AltmanMD
    • Panelist
      • Aditi ShastriMD
  • 10:05 AM – 10:35 AM

    Session 12: Case Discussions in Myeloma

    • Moderator
      • Joseph MikhaelMD, MEd, FRCPC, FACP
    • Panelist
      • Gareth MorganMD PhD
      • Saad UsmaniMD MBA FACP FASCO
    • Speaker
      • Adriana RossiMD
  • 10:35 AM – 10:45 AM

    Session 12: Post Session Survey and Q&A

    • Moderator
      • Joseph MikhaelMD, MEd, FRCPC, FACP
    • Panelist
      • Adriana RossiMD
      • Gareth MorganMD PhD
      • Saad UsmaniMD MBA FACP FASCO
  • 10:45 AM – 11:15 AM

    Exhibit Hall Break

  • 11:15 AM – 11:30 AM

    Session 13: Debate - Should Stem Cell Transplant Be Offered to Patients over 65 ? YES

    • Speaker
      • David SiegelMD, PhD
  • 11:30 AM – 11:45 AM

    Session 13: Debate - Should Stem Cell Transplant Be Offered to Patients over 65? - NO

    • Speaker
      • Ashley RoskoMD
  • 11:45 AM – 11:55 AM

    Session 13: PANEL DISCUSSION

    • Moderator
      • Joseph MikhaelMD, MEd, FRCPC, FACP
    • Panelist
      • Ashley RoskoMD
      • David SiegelMD, PhD
  • 11:55 AM – 12:25 PM

    Session 14: Multiple Myeloma: Strategies to Optimize Frontline Treatment Selection

    • Presenter
      • Joseph MikhaelMD, MEd, FRCPC, FACP
  • 12:25 PM – 12:35 PM

    Session 14: Post Session Survey and Q&A

    • Panelist
      • Joseph MikhaelMD, MEd, FRCPC, FACP
  • 12:35 PM – 12:45 PM

    Exhibit Hall Break

  • 12:45 PM – 1:45 PM

    Non-CME Innovation Theater (Sponsored by Johnson & Johnson)

  • 1:45 PM – 2:15 PM

    Session 15: Relapsed/Refractory Multiple Myeloma: Essential Strategies to Optimize the Utility of Novel and Cellular Therapies

    • Presenter
      • Noa BiranMD
  • 2:15 PM – 2:25 PM

    Session 15: Post Session Survey and Q&A

    • Panelist
      • Noa BiranMD
  • 2:25 PM – 2:40 PM

    Session 16: Debate- MRD Should Guide Therapy - YES

    • Speaker
      • Gareth MorganMD PhD
  • 2:40 PM – 2:55 PM

    Session 16: Debate- MRD Should Guide Therapy - NO

    • Speaker
      • Joshua RichterMD
  • 2:55 PM – 3:05 PM

    Session 16: PANEL DISCUSSION

    • Moderator
      • Joseph MikhaelMD, MEd, FRCPC, FACP
    • Panelist
      • Gareth MorganMD PhD
      • Joshua RichterMD
  • 3:05 PM – 3:35 PM

    Exhibit Hall Break

  • 3:35 PM – 3:50 PM

    Session 17: Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate - YES

    • Speaker
      • Andrew YeeMD
  • 3:50 PM – 4:05 PM

    Session 17: Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate - NO

    • Speaker
      • Brea LipeMD
  • 4:05 PM – 4:15 PM

    Session 17: PANEL DISCUSSION

    • Moderator
      • Joseph MikhaelMD, MEd, FRCPC, FACP
    • Panelist
      • Andrew YeeMD
      • Brea LipeMD
  • 4:15 PM – 4:30 PM

    Session 18: Debate - CAR T Cell Therapy Should Be Used as Early as Possible - YES

    • Speaker
      • Saad UsmaniMD MBA FACP FASCO
  • 4:30 PM – 4:45 PM

    Session 18: Debate - CAR T Cell Therapy Should Be Used as Early as Possible - NO

    • Speaker
      • Noopur RajeMD
  • 4:45 PM – 4:55 PM

    Session 18: PANEL DISCUSSION

    • Moderator
      • Joseph MikhaelMD, MEd, FRCPC, FACP
    • Panelist
      • Noopur RajeMD
      • Saad UsmaniMD MBA FACP FASCO